Stock Events

Beam Therapeutics 

$23.41
184
+$0.47+2.05% Friday 20:00

Statistics

Day High
23.7
Day Low
22.95
52W High
49.5
52W Low
16.95
Volume
436,932
Avg. Volume
971,678
Mkt Cap
2.2B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

4NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.42
-0.37
0.68
1.73
Expected EPS
-1.188341
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BEAM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is a direct competitor, focusing on CRISPR/Cas9 gene editing technology, similar to Beam's base editing approach.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the gene editing space using CRISPR technology, competing in the same therapeutic areas as Beam.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another key player in CRISPR gene editing, directly competing with Beam in developing gene-based therapies.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics uses zinc finger nuclease (ZFN) technology for gene editing, offering an alternative to Beam's base editing.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, which, while a different technology, competes in the genetic disease treatment market.
Ionis Pharmaceuticals
IONS
Mkt Cap6.97B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, competing in the broader market of genetic disorder treatments.
Voyager Therapeutics
VYGR
Mkt Cap357.74M
Voyager Therapeutics works on gene therapy targeting severe neurological diseases, competing for similar therapeutic applications as Beam.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio focuses on gene therapy for genetic diseases and cancer, competing in the same therapeutic areas as Beam.
Adverum Biotechnologies
ADVM
Mkt Cap144.36M
Adverum Biotechnologies develops gene therapy products for serious ocular and rare diseases, competing in the gene therapy space.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.

Analyst Ratings

52$Average Price Target
The highest estimate is $80.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
57%
Hold
43%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Show more...
CEO
John M. Evans
Employees
461
Country
US
ISIN
US07373V1052

Listings